• Resources
  • Blog
  • Journalists
  • Log In
  • Sign Up
  • Data Privacy
  • Send a Release
Cision PR Newswire: news distribution, targeting and monitoring home
  • News
  • Products
    • Overview
    • Distribution by PR Newswire
    • Cision Communications Cloud®
    • Cision IR
    • Sponsored Placement
    • All Products
  • Contact
    • General Inquiries
    • Request a Demo
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices

 

When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • English-only
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business & Money
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

      • In-Language News

      • español
      • português
      • Česko
      • Danmark
      • Deutschland
      • España
      • France
      • Italia
      • Nederland
      • Norge
      • Polska
      • Portugal
      • Россия
      • Slovensko
      • Suomi
      • Sverige
  • Overview
  • Distribution by PR Newswire
  • Cision Communications Cloud®
  • Cision IR
  • Sponsored Placement
  • All Products
  • General Inquiries
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • ALL CONTACT INFO
    • Contact Us

      888-776-0942
      from 8 AM - 10 PM ET

  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR
  • Overview
  • Distribution by PR Newswire
  • Cision Communications Cloud®
  • Cision IR
  • All Products
  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR
  • General Inquiries
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR

Urological Disorders Therapeutics to 2017 - Large Number of Licensing Deals for Approved Products Reflects a Pessimistic R&D Future


News provided by

Reportlinker

Mar 28, 2012, 04:26 ET

Share this article

Share this article


NEW YORK, March 28, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Urological Disorders Therapeutics to 2017 - Large Number of Licensing Deals for Approved Products Reflects a Pessimistic R&D Future

http://www.reportlinker.com/p0804702/Urological-Disorders-Therapeutics-to-2017---Large-Number-of-Licensing-Deals-for-Approved-Products-Reflects-a-Pessimistic-RD-Future.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

Urological Disorders Therapeutics to 2017 - Large Number of Licensing Deals for Approved Products Reflects a Pessimistic R&D Future

Summary

GBI Research's new report, "Urological Disorders Therapeutics to 2017 - Large Number of Licensing Deals for Approved Products Reflects a Pessimistic R&D Future", provides in-depth analysis of the unmet need, drivers, and barriers that impact the global urological disorders market. The report analyzes the markets for urological disorders in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, sales, prices and volumes are forecast until 2017 for the key geographies as well as the leading therapeutic segments. The report also provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions and licensing agreements that have shaped the global markets.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.

The global urological disorders market is growing rapidly with the increasing Benign Prostatic Hyperplasia (BPH) and Urinary Tract Infection (UTI) diseased populations. In 2010, the global urological disorders market was estimated to be worth $8.1 billion, representing a CAGR of 7.9% between 2002 and 2010. The BPH market, with sales worth $4.1 billion in 2010, accounted for 50% of the total urological disorders market. The UI market was estimated to be $2.4 billion, the second largest urological disorders market, and to have grown at a CAGR of 6.2% between 2002 and 2010. By 2017, the global urological disorders market is forecast to be worth $10.3 billion, representing a CAGR of 3.4% between 2010 and 2017. BPH is expected to remain the largest market in the urological disorders segment with sales of $5.7 billion in 2017. The Research and Development (R&D) pipeline for urological disorders currently has 72 molecules in different stages of clinical development. The BPH R&D pipeline accounted for approximately 39% of the total urological disorders pipeline.

The global urological disorders market is very competitive, with the top five companies accounting for 88% of the total market in 2010. Johnson & Johnson leads the market with a share of 29%. Its two main drugs are Levaquin and Elmiron, which have strong presence in the UTI and Urinary Incontinence (UI) markets respectively.

The urological disorders market has witnessed strong deal activity between 2004 and 2011. The 120 deals conducted comprised M&A deals (44), licensing deals (67) and co-development deals (nine). This growth has driven M&A activities, primarily for companies looking to expand their product portfolio for indications such as BPH, UI, UTI and Interstitial Cystitis (IC).

The urological disorders market remains attractive and is set to see moderate growth between 2010 and 2017, despite many of its blockbuster drugs going off-patent during the period.

Scope

- Annualized market data for the urological disorders market from 2002 to 2010, forecast forward to 2017.

- Analysis of the leading therapeutic segments, including UI, BPH, UTI and IC.

- Analysis of the urological disorders market in the leading geographies of the world, namely the US, the UK, Germany, France, Italy, Spain and Japan.

- Market characterization of the urological disorders market, including market size, the annual cost of therapy and treatment usage patterns.

- Key drivers and barriers that have a significant impact on the market.

- Coverage of pipeline molecules in various Phases of drug development.

- Competitive landscape of leading companies. The key companies studied in this report are Johnson & Johnson, Pfizer, GlaxoSmithKline, Astellas Pharma and Sanofi.

- Key M&A activities and licensing agreements that have taken place between 2004 and 2011 in the global urological disorders market.

Reasons to buy

- Align your product portfolio to the markets with high growth potential.

- Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth.

- Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules with more efficiency and better safety.

- Develop key strategic initiatives by understanding the key focus areas of leading companies.

- Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio gaps.

1 Table of Contents

1 Table of Contents 4

1.1 List of Tables 7

1.2 List of Figures 9

2 Urological Disorders Therapeutics to 2017 - Introduction 13

2.1 GBI Research Report Guidance 14

3 Urological Disorders Therapeutics to 2017 - Market Overview 15

3.1 Introduction 15

3.2 Revenue Forecasts for the Global Urological Disorders Market 16

3.2.1 Revenue 16

3.2.2 Generic Share 17

3.2.3 Annual Cost of Therapy 18

3.2.4 Treatment Usage Patterns 20

3.3 Urological Disorders Market Drivers and Restraints 26

3.3.1 Urological Disorders Market Drivers 26

3.3.2 Urological Disorders Market Restraints 27

4 Urological Disorders Therapeutics to 2017 - Geographical Landscape 28

4.1 Revenue by Geography 28

4.2 The US 30

4.2.1 Revenue 30

4.2.2 Annual Cost of Therapy 32

4.2.3 Treatment Usage Patterns 33

4.3 Top Five Countries in Europe 39

4.3.1 Revenue 39

4.3.2 Annual Cost of Therapy 41

4.3.3 Treatment Usage Patterns 42

4.4 Japan 48

4.4.1 Revenue 48

4.4.2 Annual Cost of Therapy 49

4.4.3 Treatment Usage Patterns 50

5 Urological Disorders Therapeutics to 2017 - Therapeutic Landscape 56

5.1 Benign Prostatic Hyperplasia Market 56

5.1.1 Introduction 56

5.1.2 Treatment Algorithm 56

5.1.3 Revenue 57

5.1.4 Annual Cost of Therapy 60

5.1.5 Treatment Usage Patterns 62

5.2 Urinary Incontinence Market 68

5.2.1 Introduction 68

5.2.2 Treatment Algorithm 69

5.2.3 Revenue 71

5.2.4 Annual Cost of Therapy 74

5.2.5 Treatment Usage Patterns 75

5.3 Urinary Tract Infections Market 81

5.3.1 Introduction 81

5.3.2 Treatment Algorithm 81

5.3.3 Revenue 82

5.3.4 Annual Cost of Therapy 85

5.3.5 Treatment Usage Patterns 86

5.4 Interstitial Cystitis Market 92

5.4.1 Introduction 92

5.4.2 Treatment Algorithm 92

5.4.3 Revenue 93

5.4.4 Annual Cost of Therapy 96

5.4.5 Treatment Usage Patterns 97

6 Urological Disorders Therapeutics to 2017 - Pipeline Product Analysis 103

6.1 Introduction 103

6.2 Product Pipeline by Indication 108

6.2.1 Benign Prostatic Hyperplasia 108

6.2.2 Urinary Incontinence 109

6.2.3 Urinary Tract Infections 110

6.2.4 Interstitial Cystitis 111

6.3 Profiles of Key Late-Stage Drugs in the Urological Disorders Market 112

6.3.1 Benign Prostatic Hyperplasia 112

6.3.2 Urinary Incontinence 114

6.3.3 Urinary Tract Infections 115

6.3.4 Interstitial Cystitis 116

7 Urological Disorders Therapeutics to 2017 - Competitive Landscape 119

7.1 Drugs for Major Urological Disorders 119

7.1.1 Duodart 119

7.1.2 Dutasteride (Avodart) 120

7.1.3 Ditropan (Oxybutynin chloride) 121

7.1.4 Tamsulosin (Flomax, Harnal) 121

7.1.5 Enablex (Darifenacin) 122

7.1.6 Sanctura XR (Trospium Chloride) 123

7.1.7 Doribax (Doripenem) 124

7.1.8 Detrol/Detrol LA (Tolterodine tartrate) 125

7.1.9 Vesicare (Solifenacin Succinate) 125

7.1.10 Alfuzosin (Xatral, Uroxatral) 126

7.1.11 Levaquin (levofloxacin) 127

7.1.12 Toviaz (Fesoterodine Fumarate) 128

7.2 Market Share Analysis 129

7.3 Competitive Profiling 130

7.3.1 Johnson & Johnson 130

7.3.2 Boehringer Ingelheim 131

7.3.3 Astellas Pharma 132

7.3.4 GlaxoSmithKline 133

7.3.5 Pfizer 134

8 Urological Disorders Therapeutics to 2017 - M&A Landscape 135

8.1 Overview 135

8.2 M&A Deals (2004-2011) 136

8.2.1 By Indication 136

8.2.2 By Year 137

8.2.3 By Deal Type 138

8.2.4 By Deal Sub-Type 139

8.2.5 Geography 140

8.2.6 Value 141

8.3 Licensing Deals 143

8.3.1 By Indication 143

8.3.2 By Year 144

8.3.3 By Geography 145

8.3.4 By Value 146

8.4 Co-Development Deals 147

8.4.1 By Indication 147

8.4.2 By Year 148

8.4.3 By Geography 149

8.4.4 By Value 150

9 Urological Disorders Therapeutics to 2017 - Appendix 151

9.1 Market Definitions 151

9.2 Abbreviations 151

9.3 Research Methodology 152

9.3.1 Coverage 152

9.3.2 Secondary Research 153

9.3.3 Primary Research 153

9.3.4 Therapeutic Landscape 154

9.3.5 Market Size by Geography 156

9.3.6 Geographical Landscape 157

9.3.7 Pipeline Analysis 157

9.3.8 Competitive Landscape 157

9.3.9 Expert Panel Validation 157

9.4 Contact Us 157

9.5 Disclaimer 157

9.6 Sources 158

1.1 List of Tables

Table 1: Urological Disorders Therapeutics to 2017, Global, Revenue ($bn), 2002-2010 16

Table 2: Urological Disorders Therapeutics to 2017, Global, Revenue Forecasts ($bn), 2010-2017 16

Table 3: Urological Disorders Therapeutics to 2017, Global, Branded Vs Generics ($bn), 2002-2010 17

Table 4: Urological Disorders Therapeutics to 2017, Global, Branded Vs Generics ($bn), 2010-2017 18

Table 5: Urological Disorders Therapeutics to 2017, Global, Annual Cost of Therapy ($), 2002-2010 19

Table 6: Urological Disorders Therapeutics to 2017, Global, Annual Cost of Therapy ($), 2010-2017 19

Table 7: Urological Disorders Therapeutics to 2017, Therapeutic Usage Patterns (million), 2002-2010 20

Table 8: Urological Disorders Therapeutics to 2017, Therapeutic Usage Patterns (million), 2010-2017 21

Table 9: Urological Disorders Therapeutics to 2017, Global, Revenue by Geography, ($bn), 2002-2010 29

Table 10: Urological Disorders Therapeutics to 2017, Global, Revenue by Geography, ($bn), 2010-2017 29

Table 11: Urological Disorders Therapeutics to 2017, The US, Revenue ($bn), 2002-2010 30

Table 12: Urological Disorders Therapeutics to 2017, The US, Revenue Forecasts ($bn), 2010-2017 31

Table 13: Urological Disorders Therapeutics to 2017, The US, Annual Cost of Therapy ($), 2002-2010 32

Table 14: Urological Disorders Therapeutics to 2017, The US, Annual Cost of Therapy ($), 2010-2017 32

Table 15: Urological Disorders Therapeutics to 2017, The US, Therapeutic Usage Patterns (million), 2002-2010 34

Table 16: Urological Disorders Therapeutics to 2017, The US, Therapeutic Usage Patterns (million), 2010-2017 34

Table 17: Urological Disorders Therapeutics to 2017, Top Five Countries of Europe, Revenue ($m), 2002-2010 39

Table 18: Urological Disorders Therapeutics to 2017, Top Five Countries of Europe, Revenue Forecasts ($m), 2010-2017 40

Table 19: Urological Disorders Therapeutics to 2017, Top Five Countries of Europe, Annual Cost of Therapy ($), 2002-2010 41

Table 20: Urological Disorders Therapeutics to 2017, Top Five Countries of Europe, Annual Cost of Therapy ($), 2010-2017 41

Table 21: Urological Disorders Therapeutics to 2017, Top Five Countries of Europe, Therapeutic Usage Patterns (million), 2002-2010 43

Table 22: Urological Disorders Therapeutics to 2017, Top Five Countries of Europe, Therapeutic Usage Patterns (million), 2010-2017 43

Table 23: Urological Disorders Therapeutics to 2017, Japan, Revenue ($m), 2002-2010 48

Table 24: Urological Disorders Therapeutics to 2017, Japan, Revenue Forecasts ($m), 2010-2017 48

Table 25: Urological Disorders Therapeutics to 2017, Japan, Annual Cost of Therapy ($), 2002-2010 49

Table 26: Urological Disorders Therapeutics to 2017, Japan, Annual Cost of Therapy ($), 2010-2017 50

Table 27: Urological Disorders Therapeutics to 2017, Japan, Therapeutic Usage Patterns (million), 2002-2010 51

Table 28: Urological Disorders Therapeutics to 2017, Japan, Therapeutic Usage Patterns (million), 2010-2017 51

Table 29: Urological Disorders Therapeutics to 2017, Global, Benign Prostatic Hyperplasia Revenue ($bn), 2002-2010 58

Table 30: Urological Disorders Therapeutics to 2017, Global, Benign Prostatic Hyperplasia Revenue Forecasts ($bn), 2010-2017 58

Table 31: Urological Disorders Therapeutics to 2017, Global, Benign Prostatic Hyperplasia Branded Vs Generics ($bn), 2002-2010 59

Table 32: Urological Disorders Therapeutics to 2017, Global, Benign Prostatic Hyperplasia Branded Vs Generics ($bn), 2010-2017 59

Table 33: Urological Disorders Therapeutics to 2017, Global, Benign Prostatic Hyperplasia Annual Cost of Therapy ($), 2002-2010 60

Table 34: Urological Disorders Therapeutics to 2017, Global, Benign Prostatic Hyperplasia Annual Cost of Therapy ($), 2010-2017 61

Table 35: Urological Disorders Therapeutics to 2017, Global, Benign Prostatic Hyperplasia Treatment Usage Patterns (million), 2002-2010 62

Table 36: Urological Disorders Therapeutics to 2017, Global, Benign Prostatic Hyperplasia Treatment Usage Patterns (million), 2010-2017 63

Table 37: Urological Disorders Therapeutics to 2017, Global, Urinary Incontinence Revenue ($bn), 2002-2010 71

Table 38: Urological Disorders Therapeutics to 2017, Global, Urinary Incontinence Revenue Forecasts ($bn), 2010-2017 71

Table 39: Urological Disorders Therapeutics to 2017, Global, Urinary Incontinence Branded Vs Generics ($m), 2002-2010 72

Table 40: Urological Disorders Therapeutics to 2017, Global, Urinary Incontinence Branded Vs Generics ($m), 2010-2017 73

Table 41: Urological Disorders Therapeutics to 2017, Global, Urinary Incontinence Annual Cost of Therapy ($), 2002-2010 74

Table 42: Urological Disorders Therapeutics to 2017, Global, Urinary Incontinence Annual Cost of Therapy ($), 2010-2017 74

Table 43: Urological Disorders Therapeutics to 2017, Global, Urinary Incontinence Treatment Usage Patterns (million), 2002-2010 75

Table 44: Urological Disorders Therapeutics to 2017, Global, Urinary Incontinence Treatment Usage Patterns (million), 2010-2017 76

Table 45: Urological Disorders Therapeutics to 2017, Global, Urinary Tract Infection Revenue ($bn), 2002-2010 82

Table 46: Urological Disorders Therapeutics to 2017, Global, Urinary Tract Infection Revenue Forecasts ($bn), 2010-2017 83

Table 47: Urological Disorders Therapeutics to 2017, Global, Urinary Tract Infection Branded Vs Generics ($bn), 2002-2010 84

Table 48: Urological Disorders Therapeutics to 2017, Global, Urinary Tract Infection Branded Vs Generics ($bn), 2010-2017 84

Table 49: Urological Disorders Therapeutics to 2017, Global, Urinary Tract Infection Annual Cost of Therapy ($), 2002-2010 85

Table 50: Urological Disorders Therapeutics to 2017, Global, Urinary Tract Infection Annual Cost of Therapy ($), 2010-2017 85

Table 51: Urological Disorders Therapeutics to 2017, Global, Urinary Tract Infection Treatment Usage Patterns (million), 2002-2010 86

Table 52: Urological Disorders Therapeutics to 2017, Global, Urinary Tract Infection Treatment Usage Patterns (million), 2010-2017 87

Table 53: Urological Disorders Therapeutics to 2017, Global, Interstitial Cystitis Revenue ($m), 2002-2010 93

Table 54: Urological Disorders Therapeutics to 2017, Global, Interstitial Cystitis Revenue Forecasts ($m), 2010-2017 94

Table 55: Urological Disorders Therapeutics to 2017, Global, Interstitial Cystitis Branded Vs Generics ($m), 2002-2010 95

Table 56: Urological Disorders Therapeutics to 2017, Global, Interstitial Cystitis Branded Vs Generics ($m), 2010-2017 95

Table 57: Urological Disorders Therapeutics to 2017, Global, Interstitial Cystitis Annual Cost of Therapy ($), 2002-2010 96

Table 58: Urological Disorders Therapeutics to 2017, Global, Interstitial Cystitis Annual Cost of Therapy ($), 2010-2017 96

Table 59: Urological Disorders Therapeutics to 2017, Global, Interstitial Cystitis Treatment Usage Patterns ('000), 2002-2010 97

Table 60: Urological Disorders Therapeutics to 2017, Global, Interstitial Cystitis Treatment Usage Patterns ('000), 2010-2017 98

Table 61: Urological Disorders Therapeutics to 2017, Pipeline Products, 2010 105

Table 62: Urological Disorders Therapeutics to 2017, Key Pipeline Products, Mechanism of Action, 2010 107

Table 63: Urological Disorders Therapeutics to 2017, Global, Number of Deals by Indication, 2004-2011 135

Table 64: Urological Disorders Therapeutics to 2017, Global, Number of M&A Deals by Indication, 2004-2011 136

Table 65: Urological Disorders Therapeutics to 2017, Global, Number of M&A Deals, 2004-2011 137

Table 66: Urological Disorders Therapeutics to 2017, Global, Number of M&A Deals by Deal Type, 2004-2011 138

Table 67: Urological Disorders Therapeutics to 2017, Global, Number of M&A Deals by Deal Sub-Type, 2004-2011 139

Table 68: Urological Disorders Therapeutics to 2017, Global, Number of M&A Deals by Geography, 2004-2011 140

Table 69: Urological Disorders Therapeutics to 2017, Global, Number of M&A Deals by Value, 2004-2011 141

Table 70: Urological Disorders Therapeutics to 2017, Global, Top Five M&A Deals, 2005-2011 142

Table 71: Urological Disorders Therapeutics to 2017, Global, Number of Licensing Agreements by Indication, 2004-2011 143

Table 72: Urological Disorders Therapeutics to 2017, Global, Number of Licensing Agreements, 2004-2011 144

Table 73: Urological Disorders Therapeutics to 2017, Global, Number of Licensing Agreements by Geography, 2004-2011 145

Table 74: Urological Disorders Therapeutics to 2017, Global, Number of Licensing Agreements by Value, 2004-2011 146

Table 75: Urological Disorders Therapeutics to 2017, Global, Number of Co-Development Deals by Indication, 2004-2010 147

Table 76: Urological Disorders Therapeutics to 2017, Global, Number of Co-Development Deals, 2004-2010 148

Table 77: Urological Disorders Therapeutics to 2017, Global, Number of Co-Development Deals by Geography, 2004-2010 149

Table 78: Urological Disorders Therapeutics to 2017, Global, Number of Co-Development Deals by Value, 2004-2010 150

1.2 List of Figures

Figure 1: Urological Disorders Therapeutics to 2017, Global, Share of Major Urological Disorders, Revenue(%), 2010 15

Figure 2: Urological Disorders Therapeutics to 2017, Global, Revenue Forecasts ($bn), 2002-2017 16

Figure 3: Urological Disorders Therapeutics to 2017, Global, Branded Vs Generics ($bn), 2002-2017 17

Figure 4: Urological Disorders Therapeutics to 2017, Global, Annual Cost of Therapy ($), 2002-2017 18

Figure 5: Urological Disorders Therapeutics to 2017, Therapeutic Usage Patterns (million), 2002-2017 20

Figure 6: Urological Disorders Therapeutics to 2017, Diseased Population (million), 2002-2017 22

Figure 7: Urological Disorders Therapeutics to 2017, Treatment Seeking Population (million), 2002-2017 23

Figure 8: Urological Disorders Therapeutics to 2017, Diagnosis Population (million), 2002-2017 24

Figure 9: Urological Disorders Therapeutics to 2017, Prescription Population (million), 2002-2017 25

Figure 10: Urological Disorders Therapeutics to 2017, Global, Drivers and Restraints, 2010 26

Figure 11: Urological Disorders Therapeutics to 2017, Global, Revenue by Geography, ($bn), 2010 28

Figure 12: Urological Disorders Therapeutics to 2017, The US, Revenue Forecasts ($bn), 2002-2017 30

Figure 13: Urological Disorders Therapeutics to 2017, The US, Annual Cost of Therapy ($), 2002-2017 32

Figure 14: Urological Disorders Therapeutics to 2017, The US, Therapeutic Usage Patterns (million), 2002-2017 33

Figure 15: Urological Disorders Therapeutics to 2017, The US, Diseased Population (million), 2002-2017 35

Figure 16: Urological Disorders Therapeutics to 2017, The US, Treatment Seeking Population (million), 2002-2017 36

Figure 17: Urological Disorders Therapeutics to 2017, The US, Diagnosis Population (million), 2002-2017 37

Figure 18: Urological Disorders Therapeutics to 2017, The US, Prescription Population (million), 2002-2017 38

Figure 19: Urological Disorders Therapeutics to 2017, Top Five Countries of Europe, Revenue Forecasts ($m), 2002-2017 39

Figure 20: Urological Disorders Therapeutics to 2017, Top Five Countries of Europe, Annual Cost of Therapy ($), 2002-2017 41

Figure 21: Urological Disorders Therapeutics to 2017, Top Five Countries of Europe, Therapeutic Usage Patterns (million), 2002-2017 42

Figure 22: Urological Disorders Therapeutics to 2017, Top Five Countries of Europe, Diseased Population (million), 2002-2017 44

Figure 23: Urological Disorders Therapeutics to 2017, Top Five Countries of Europe, Treatment Seeking Population (million), 2002-2017 45

Figure 24: Urological Disorders Therapeutics to 2017, Top Five Countries of Europe, Diagnosis Population (million), 2002-2017 46

Figure 25: Urological Disorders Therapeutics to 2017, Top Five Countries of Europe, Prescription Population (million), 2002-2017 47

Figure 26: Urological Disorders Therapeutics to 2017, Japan, Revenue Forecasts ($m), 2002-2017 48

Figure 27: Urological Disorders Therapeutics to 2017, Japan, Annual Cost of Therapy ($), 2002-2017 49

Figure 28: Urological Disorders Therapeutics to 2017, Japan, Therapeutic Usage Patterns (million), 2002-2017 50

Figure 29: Urological Disorders Therapeutics to 2017, Japan, Diseased Population (million), 2002-2017 52

Figure 30: Urological Disorders Therapeutics to 2017, Japan, Treatment Seeking Population (million), 2002-2017 53

Figure 31: Urological Disorders Therapeutics to 2017, Japan, Diagnosis Population (million), 2002-2017 54

Figure 32: Urological Disorders Therapeutics to 2017, Japan, Prescription Population (million), 2002-2017 55

Figure 33: Urological Disorders Therapeutics to 2017, BPH Treatment Algorithm 56

Figure 34: Urological Disorders Therapeutics to 2017, Global, BPH Revenue Forecasts ($bn), 2002-2017 57

Figure 35: Urological Disorders Therapeutics to 2017, Global, Benign Prostatic Hyperplasia Branded Vs Generics ($bn), 2002-2017 59

Figure 36: Urological Disorders Therapeutics to 2017, Global, Benign Prostatic Hyperplasia Annual Cost of Therapy ($), 2002-2017 60

Figure 37: Urological Disorders Therapeutics to 2017, Global, Benign Prostatic Hyperplasia Treatment Usage Patterns (million), 2002-2017 62

Figure 38: Urological Disorders Therapeutics to 2017, Global, Benign Prostatic Hyperplasia Diseased Population (million), 2002-2017 64

Figure 39: Urological Disorders Therapeutics to 2017, Global, Benign Prostatic Hyperplasia Treatment Seeking Population (million), 2002-2017 65

Figure 40: Urological Disorders Therapeutics to 2017, Global, Benign Prostatic Hyperplasia Diagnosis Population (million), 2002-2017 66

Figure 41: Urological Disorders Therapeutics to 2017, Global, Benign Prostatic Hyperplasia Prescription Population (million), 2002-2017 67

Figure 42: Urological Disorders Therapeutics to 2017, Urinary Incontinence Treatment Algorithm Part 1 69

Figure 43: Urological Disorders Therapeutics to 2017, Urinary Incontinence Treatment Algorithm, Part-2 70

Figure 44: Urological Disorders Therapeutics to 2017, Global, Urinary Incontinence Revenue Forecasts ($bn), 2002-2017 71

Figure 45: Urological Disorders Therapeutics to 2017, Global, Urinary Incontinence Branded Vs Generics ($m), 2002-2017 72

Figure 46: Urological Disorders Therapeutics to 2017, Global, Urinary Incontinence Annual Cost of Therapy ($), 2002-2017 74

Figure 47: Urological Disorders Therapeutics to 2017, Global, Urinary Incontinence Treatment Usage Patterns (million), 2002-2017 75

Figure 48: Urological Disorders Therapeutics to 2017, Global, Urinary Incontinence Diseased Population (million), 2002-2017 77

Figure 49: Urological Disorders Therapeutics to 2017, Global, Urinary Incontinence Treatment Seeking Population (million), 2002-2017 78

Figure 50: Urological Disorders Therapeutics to 2017, Global, Urinary Incontinence Diagnosis Population (million), 2002-2017, 79

Figure 51: Urological Disorders Therapeutics to 2017, Global, Urinary Incontinence Prescription Population (million), 2002-2017 80

Figure 52: Urological Disorders Therapeutics to 2017, Urinary Tract Infection Treatment Algorithm 81

Figure 53: Urological Disorders Therapeutics to 2017, Global, Urinary Tract Infection Revenue Forecasts ($bn), 2002-2017 82

Figure 54: Urological Disorders Therapeutics to 2017, Global, Urinary Tract Infection Branded Vs Generics ($m), 2002-2017 83

Figure 55: Urological Disorders Therapeutics to 2017, Global, Urinary Tract Infection Annual Cost of Therapy ($), 2002-2017 85

Figure 56: Urological Disorders Therapeutics to 2017, Global, Urinary Tract Infection Treatment Usage Patterns (million), 2002-2017 86

Figure 57: Urological Disorders Therapeutics to 2017, Global, Urinary Tract Infection Diseased Population (million), 2002-2017 88

Figure 58: Urological Disorders Therapeutics to 2017, Global, Urinary Tract Infection Treatment Seeking Population (million), 2002-2017 89

Figure 59: Urological Disorders Therapeutics to 2017, Global, Urinary Tract Infection Diagnosis Population (million), 2002-2017 90

Figure 60: Urological Disorders Therapeutics to 2017, Global, Urinary Tract Infection Prescription Population (million), 2002-2017 91

Figure 61: Urological Disorders Therapeutics to 2017, Interstitial Cystitis Treatment Algorithm 92

Figure 62: Urological Disorders Therapeutics to 2017, Global, Interstitial Cystitis Revenue Forecasts ($m), 2002-2017 93

Figure 63: Urological Disorders Therapeutics to 2017, Global, Interstitial Cystitis Branded Vs Generics ($m), 2002-2017 94

Figure 64: Urological Disorders Therapeutics to 2017, Global, Interstitial Cystitis Annual Cost of Therapy ($), 2002-2017 96

Figure 65: Urological Disorders Therapeutics to 2017, Global, Interstitial Cystitis Treatment Usage Patterns ('000), 2002-2017 97

Figure 66: Urological Disorders Therapeutics to 2017, Global, Interstitial Cystitis Diseased Population (million), 2002-2017 99

Figure 67: Urological Disorders Therapeutics to 2017, Global, Interstitial Cystitis Treatment Seeking Population (million), 2002-2017 100

Figure 68: Urological Disorders Therapeutics to 2017, Global, Interstitial Cystitis Diagnosis Population (million), 2002-2017 101

Figure 69: Urological Disorders Therapeutics to 2017, Global, Interstitial Cystitis Prescription Population (million), 2002-2017 102

Figure 70: Urological Disorders Therapeutics to 2017, Global, R&D Pipeline by Indication (%), 2011 103

Figure 71: Urological Disorders Therapeutics to 2017, Global, R&D Pipeline by Phase (%), 2011 104

Figure 72: Urological Disorders Therapeutics to 2017, R&D Pipeline by Phase in Benign Prostatic Hyperplasia Market (%), 2011 108

Figure 73: Urological Disorders Therapeutics to 2017, R&D Pipeline by Phase in Urinary Incontinence Market (%), 2011 109

Figure 74: Urological Disorders Therapeutics to 2017, R&D Pipeline by Phase in Urinary Tract Infection Market (%), 2011 110

Figure 75: Urological Disorders Therapeutics to 2017, R&D Pipeline by Phase in Interstitial Cystitis Market (%), 2011 111

Figure 76: Urological Disorders Therapeutics to 2017, Global, Market Share of Top Manufacturers (%), 2010 129

Figure 77: Urological Disorders Therapeutics to 2017, SWOT Analysis of Johnson & Johnson, 2011 130

Figure 78: Urological Disorders Therapeutics to 2017, SWOT Analysis of Boehringer Ingelheim, 2011 131

Figure 79: Urological Disorders Therapeutics to 2017, SWOT Analysis of Astellas Pharma, 2011 132

Figure 80: Urological Disorders Therapeutics to 2017, SWOT Analysis of GlaxoSmithKline, 2011 133

Figure 81: Urological Disorders Therapeutics to 2017, SWOT Analysis of Pfizer, 2011 134

Figure 82: Urological Disorders Therapeutics to 2017, Global, Deals by Indication (%), 2004-2011 135

Figure 83: Urological Disorders Therapeutics to 2017, Global, M&A Deals by Indication (%), 2004-2011 136

Figure 84: Urological Disorders Therapeutics to 2017, Global, Number of M&A Deals, 2004-2011 137

Figure 85: Urological Disorders Therapeutics to 2017, Global, M&A Deals by Deal Type (%), 2004-2011 138

Figure 86: Urological Disorders Therapeutics to 2017, Global, M&A Deals by Sub Deal Type (%), 2004-2011 139

Figure 87: Urological Disorders Therapeutics to 2017, Global, M&A Deals by Geography (%), 2004-2011 140

Figure 88: Urological Disorders Therapeutics to 2017, Global, M&A Deals by Value (%), 2004-2011 141

Figure 89: Urological Disorders Therapeutics to 2017, Global, Licensing Agreements by Indication (%), 2004-2011 143

Figure 90: Urological Disorders Therapeutics to 2017, Global, Number of Licensing Agreements, 2004-2011 144

Figure 91: Urological Disorders Therapeutics to 2017, Global, Licensing Agreements by Geography (%), 2004-2011 145

Figure 92: Urological Disorders Therapeutics to 2017, Global, Licensing Agreements by Value (%), 2004-2011 146

Figure 93: Urological Disorders Therapeutics to 2017, Global, Co-Development Deals by Indication (%), 2004-2010 147

Figure 94: Urological Disorders Therapeutics to 2017, Global, Number of Co-Development Deals, 2004-2010 148

Figure 95: Urological Disorders Therapeutics to 2017, Global, Co-Development Deals by Geography (%), 2004-2010 149

Figure 96: Urological Disorders Therapeutics to 2017, Global, Co-Developments Deals by Value (%), 2004-2010 150

Figure 97: GBI Research Market Forecasting Model 156

Companies mentioned

Johnson & Johnson

Boehringer Ingelheim

Astellas Pharma

GlaxoSmithKline

Pfizer

To order this report:

Pathology Industry: Urological Disorders Therapeutics to 2017 - Large Number of Licensing Deals for Approved Products Reflects a Pessimistic R&D Future

More  Market Research Report

Check our  Industry Analysis and Insights

CONTACT:
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker

Modal title

Contact Cision

  • Cision Distribution 888-776-0942
    from 8 AM - 9 PM ET

  • Chat with an Expert
  • General Inquiries
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices

Products

  • Cision Communication Cloud®
  • For Marketers
  • For Public Relations
  • For IR & Compliance
  • For Agency
  • For Small Business
  • All Products

About

  • About PR Newswire
  • About Cision
  • Become a Publishing Partner
  • Become a Channel Partner
  • Careers
  • COVID-19 Resources
  • Accessibility Statement
  • Asia
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Israel
  • Italy
  • Mexico
  • Middle East
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom

My Services

  • All New Releases
  • Online Member Center
  • ProfNet

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2022 Cision US Inc.